(PDF) Real-World Experience of Afatinib as a First-Line

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

Oncotarget - United States

doi 10.18632/oncotarget.19563

Full Text

Open PDF

Abstract

Available in full text

Date

July 26, 2017

Authors

Publisher

Impact Journals, LLC

Related search

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology

English

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Journal of Thoracic Oncology

English

P1.15-19 Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real World Data

Journal of Thoracic Oncology

English

P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients With EGFR Mutation-Positive Advanced NSCLC

Journal of Thoracic Oncology

English

Healthcare Resource Utilization and Costs Associated With Patients Prescribed Afatinib or Erlotinib as First-Line Therapy for EGFR Mutation-Positive NSCLC in the United States

Journal of Medical Economics

Health Policy

2019

English

The Profile of Lung Adenocarcinoma Patients With Positive EGFR Mutation

Green Medical Journal

2020

English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Neoplasma

Cancer Research

2013

English

P1.13-12 EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma

Journal of Thoracic Oncology

English

Amanote Research

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

Oncotarget - United States

doi 10.18632/oncotarget.19563

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

P1.15-19 Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real World Data

P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients With EGFR Mutation-Positive Advanced NSCLC

Healthcare Resource Utilization and Costs Associated With Patients Prescribed Afatinib or Erlotinib as First-Line Therapy for EGFR Mutation-Positive NSCLC in the United States

The Profile of Lung Adenocarcinoma Patients With Positive EGFR Mutation

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

P1.13-12 EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma